Wave Life Sciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Wave Life Sciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 1,071% in 3 years, but profit fell: $109 less profit per $100 of extra sales. Lower than 87% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 89% of its market value (net cash). Higher than 87% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-129.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 85% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
−$109Sales grew 1,071% in 3 years, but profit fell: $109 less profit per $100 of extra sales.
Lower than 87% of Healthcare companies in United States.
Asset Productivity Ratio
+1071% / +336%In 3 years sales changed by +1071% while total assets changed by +336%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-22.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 57% of Healthcare companies in United States.
Cash Cushion Ratio
+89%Cash, after subtracting all debt, equals 89% of its market value (net cash).
Higher than 87% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Wave Life Sciences, Inc. made a loss over the last year. Wave Life Sciences, Inc. owes $0.19 for every $1 it owns. Wave Life Sciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossWave Life Sciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.38The share price is 1.38 times Wave Life Sciences, Inc.'s book value per share, lower than 71% of Healthcare companies in United States.
Market cap
$627 MThe total market value of all of Wave Life Sciences, Inc.'s shares at today's price (share price × number of shares), larger than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$454 MWhat Wave Life Sciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.30Net worth divided by the number of shares. The share price of $3.18 is 1.4 times this, which is the P/B above.
Return on equity (ROE)
-67.4%Wave Life Sciences, Inc. lost 67.4% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
Owes vs Owns
0.19×Wave Life Sciences, Inc. owes $0.19 for every $1 it owns (low), lower than 74% of Healthcare companies in United States.
Dividend yield
NoneWave Life Sciences, Inc. does not currently pay a dividend.
Revenue growth
-61%Revenue fell 61% in the year to Dec 2025, and grew 127% a year on average over 3 years.
Profit growth
LossWave Life Sciences, Inc. made a loss in each of the last two years.
Profit margin
-478.3%Wave Life Sciences, Inc. lost $478 for every $100 of revenue.
Cash vs debt
Net cashWave Life Sciences, Inc. held $584 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Wave Life Sciences, Inc.: $627 M ÷ $454 M (30 Jun 2026) = 1.4.
What is Wave Life Sciences, Inc.'s return on equity?
Wave Life Sciences, Inc. lost 67.4% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
How much does Wave Life Sciences, Inc. owe compared with what it owns?
Wave Life Sciences, Inc. owes $0.19 for every $1 it owns (low), lower than 74% of Healthcare companies in United States.
Does Wave Life Sciences, Inc. pay a dividend?
No. Wave Life Sciences, Inc. does not currently pay a dividend.
Is Wave Life Sciences, Inc.'s revenue growing?
Revenue fell 61% in the year to Dec 2025, and grew 127% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.